Comparative Pharmacology
Head-to-head clinical analysis: ANGIOMAX versus PRADAXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOMAX versus PRADAXA.
ANGIOMAX vs PRADAXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, blocking its interaction with substrates, thereby inhibiting fibrin formation and activation of coagulation factors V, VIII, and XIII.
Direct thrombin inhibitor; binds reversibly to the active site of thrombin, preventing fibrinogen cleavage and subsequent thrombus formation.
1 mg/kg intravenous bolus followed by 0.1 mg/kg/hour continuous intravenous infusion for duration of procedure; alternatively, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg/hour continuous intravenous infusion for up to 4 hours during percutaneous coronary intervention.
150 mg orally twice daily; for patients with CrCl 15-30 mL/min, 75 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 25-30 minutes in patients with normal renal function; increased to 2-3 hours in dialysis-dependent patients
12–17 hours (terminal); prolonged to 18–35 hours in severe renal impairment (CrCl <30 mL/min); supports twice-daily dosing
Renal: ~90% unchanged; biliary/fecal: negligible (<1%)
Renal (80% unchanged); fecal/biliary (20% as inactive metabolites via P-glycoprotein-mediated secretion)
Category C
Category C
Anticoagulant
Anticoagulant